17:03 EDT I-Mab (IMAB) files $250M mixed securities shelf
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMAB:
- I-Mab’s Givastomig Study Accepted for ESMO GI 2025 Presentation
- I-Mab’s Transformative Year: Financial and Strategic Highlights
- I-Mab Positions for Growth with U.S. Focus and Innovative Cancer Treatments
- Promising Pipeline and Strong Financial Position Drive Buy Rating for I-Mab
- I-Mab price target lowered to $7 from $8 at H.C. Wainwright